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options for infections caused by multidrug-resistant (MDR)
bacteria, the use of old drugs that retain activity against MDR
organisms becomes attractive. Old drugs that have been
recently revived include colistin, temocillin, fosfomycin, mecil-
linam, nitrofurantoin and chloramphenicol for MDR Gram-
negative bacteria and trimethoprim-sulfamethoxazole for
methicillin-resistant Staphylococcus aureus. These old antibiotics
have never been characterized in a structured process for drug
assessment and lack regulatory approval according to current
standards. In response to the increasing use of old antibiotics,
several publicly funded initiatives have recently been formed to
generate essential information or even re-develop revived an-
tibiotics. Coordinated initiatives are necessary to identify a
structured process to maximize the potential of these impor-
tant drugs and ensure that we do not lose them quickly to
resistance. Discussions of various pathways for creating this
structured process were held at the recent ESCMID confer-
ence on the Revival of old antibiotics [1] and some of the topics
are summarized in the current theme issue.Dosing and breakpoint re-assessmentModern analytical methods for accurate quantiﬁcation of anti-
biotics in biological ﬂuids must be applied to the pharmacoki-
netic (PK) characterization of revived antibiotics. At the time
when old antibiotics were approved, dosing regimens were
established with little scientiﬁc rationale and partly based on
now obsolete PK methods. Colistin is the most prominentMicrobiol Infect 2015; 21: 878–880
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.06.019example, which has dosing recommendations derived from PK
data that did not differentiate the non-active prodrug from the
active drug [2]. As new PK/pharmacodynamic (PD) and high-
quality clinical data are generated for the old antibiotics,
dosing regimens and breakpoints need to be re-assessed and
adapted. Sime et al., in the current issue, review the PK/PD
variations that occur in special patient populations [3]. The
authors encourage therapeutic drug monitoring and population
PK models to predict the dosing needs of individual patients
based on PK data and clinical variables. Muller et al. review the
lack of such data for old antibiotics and provide suggestions to
address the PK/PD perspective in the re-development process
of old antibiotics [4].Generating high-quality clinical evidenceSystematic reviews attempting to summarize data on the
effectiveness of old antibiotics such as nitrofurantoin [5],
fosfomycin-trometamol [6], chloramphenicol [7] and colistin
[8] point mainly at deﬁciencies in the available evidence. At the
time when old antibiotics were ﬁrst approved there was no
guidance on the minimal evidence-base required for a drug’s
efﬁcacy and safety before it entered clinical use. There were no
recommendations on the design and reporting of randomized
controlled trials (RCTs). Furthermore, these revived drugs are
now considered for indications other than those for which they
were originally developed and used. For example, the use of
trimethoprim-sulfamethoxazole for methicillin-resistant Staph-
ylococcus aureus [9] and intravenous fosfomycin for severe in-
fections caused by MDR Gram-negative bacteria [10]. Evidence
for clinical efﬁcacy and safety needs to be generated for the
indications for which the old drugs are currently intended.
Combination regimens involving old antibiotics must be
examined in RCTs [8]. Manufacturers of generic antibioticsious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Editorial 879have no incentive to generate such evidence, so public funding
is required. Laterre and François present the advantages and
limitations of academic versus industry-sponsored RCTs [11].
The authors make a strong point in favour of an academic–
industry collaboration that could improve both types of
research.International drug availabilityNot all of the revived antibiotics are licensed in all countries. In
a survey of antibiotic availability in 38 countries in Europe, the
USA, Canada and Australia, overall two-thirds of the 33 anti-
biotics examined were available in fewer than half of the
countries [12]. This was especially the case for old antibiotics.
Different preparations of colistin are marketed in Europe and in
the USA, which impedes direct comparisons of drug effects
[13]. Again it is in the public’s interest to incentivize production,
approval and distribution of high-quality old drugs to ensure
uniform drug availability globally.Generating global susceptibility dataRevived antibiotics are typically not part of international resis-
tance surveillance programs and are not included in the routine
panels of automated antibiotic susceptibility testing systems.
We currently depend on regional or, more commonly,
hospital-speciﬁc information to monitor resistance trends. Se-
lective testing of MDR bacteria in individual hospitals or speciﬁc
settings might lead to susceptibility data biased towards resis-
tance. The need for incorporating testing of the old drugs into
antibiotic resistance surveillance systems is exempliﬁed by the
increasing resistance rates to colistin among carbapenemase-
producing Enterobacteriaceae that are reported in some loca-
tions [14]. Giske reviews contemporary resistance trends for
several old drugs [15].Minimizing resistance developmentMany factors determine the risk of the evolution of resistance to
an antibiotic, beyond the individual optimal drug exposure at the
site of infection. Understanding this risk for old antibiotics might
allow for improved usage and better triage of which antibiotics to
invest in. Anderson points to the limitations of currently available
data on prediction of the emergence of antibiotic resistance [16].
The author recommends more complex modelling, comprising
metagenomic analyses, ﬁtness assessments and PK/PD analyses to
adequately predict resistance [16].Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyUpdating regulatory approvals, indications
and dosing recommendationsIn most cases of drugs that were approved decades ago, the
ofﬁcial product information refers to original data that may be
insufﬁcient or simply wrong. This is especially the case for PK
data and dosing recommendations. Additionally, in Europe, old
drugs were approved by national agencies resulting in differ-
ences in product information among countries and a surpris-
ingly wide variety of different recommendations [17]. There are
almost no established regulatory pathways for incorporating
new updated drug product information for old antibiotics [1].
There is clearly a need for harmonization of procedures be-
tween all of the main regulatory agencies worldwide. Correct
and updated product information is a prerequisite for inte-
grating new knowledge in guidelines and treatment
recommendations.
In summary, the research and development pipeline for an-
tibiotics lags behind contemporary needs and old antibiotics are
increasingly used for the treatment of MDR infections. Using
antibiotics based on the knowledge and data generated decades
ago is unacceptable in modern medicine. The re-development
process for revived old antibiotics in academic settings ur-
gently needs to be coordinated, funded and translated into
clinical practice.AcknowledgementsThis work was partly supported by the EU 7th Framework Pro-
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